Sheila Mikhail has over 20 years of biopharmaceutical leadership experience and is Chief Executive Officer and co-founder of Asklepios BioPharmaceutical, Inc. (AskBio), a company she started in 2001. She most recently served as Chief Executive Officer and co-founder of Bamboo Therapeutics, which in 20 months raised $50 million, advanced a therapeutic for GAN into the clinic, completed pre-IND studies for a Duchenne muscular dystrophy therapeutic, and built a GMP manufacturing facility. Bamboo was acquired by Pfizer in August 2016 in a deal valued at $827 million. Prior to that, she was part of the management team at Chatham Therapeutics, which was acquired by Baxter in 2014. Ms. Mikhail practiced law for more than 15 years. During that time, she founded Life Sciences Law, which serviced clients including Bayer, Gilead, GSK, Sanofi and Aventis. She also practiced with Ropes and Gray in Boston.

She earned a JD with honors from Northwestern University, a finance MBA with honors from the University of Chicago, and a BS with highest honors from the University of Illinois at Urbana-Champaign.